证券代码：300253 证券简称：卫宁健康 卫宁健康科技集团股份有限公司 投资者关系活动记录表 编号：2018-006 | --- | --- | --- | |-------------------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300253 证券简称：卫宁健康 卫宁健康科技集团股份有限公司 投资者关系活动记录表 编号：2018-007 | --- | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300253 证券简称：卫宁健康 | --- | --- | --- | |------------------|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：300253 证券简称：卫宁健康 卫宁健康科技集团股份有限公司 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | |------------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2021-002 证券代码：300253 证券简称：卫宁健康 卫宁健康科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300253 证券简称：卫宁健康 卫宁健康科技集团股份有限公司 投资者关系活动记录表 编号：2021-004 | --- | --- | --- | |------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300253 证券简称：卫宁健康 2. 卫宁健康科技集团股份有限公司 投资者关系活动记录表 编号：2021-005 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动类 | √ 特定对象调研 | □ 分析师会议 | | 别 | □ 媒体采访 □ | ...

Financial Performance - In the first half of 2022, the company's revenue increased by 6.98% year-on-year, while net profit attributable to shareholders decreased by 21.25% [1] - The core software sales and technical services accounted for 71.03% of total revenue, with a year-on-year growth of 10.12% [1] - Hardware sales revenue decreased by 26.95%, accounting for 18.49% of total revenue in the previous year [1] - Internet healthcare business revenue grew by 40.69%, representing 16.34% of total revenue, compared to 12.43% in the same period last year [2] Impact of COVID-19 - The severe COVID-19 outbreak in Shanghai from late March to early June disrupted normal operations for over two months, negatively affecting business development [2] - The company signed 26 new contracts worth over 10 million, including 11 WiNEX projects, showing a significant increase from 16 in the same period last year [2] Product Development and Market Position - The WiNEX system, launched in 2020, is gaining traction among major clients, with 11 significant contracts signed in the first half of 2022 [5][9] - The company aims to increase its market share from 12-13% to over 20% in the coming years, leveraging the growing demand for its innovative products [6][7] - The company is confident that the long-term benefits of its new products will outweigh the increased costs associated with research and development [3] Revenue Collection and Financial Outlook - The company reported a 37% increase in cash collection in Q1 and a 27% increase in the first half of the year compared to the previous year [3] - If the pandemic remains controllable and projects are delivered on time, the company expects a reduction in bad debt provisions compared to last year [3] Industry Trends and Competitive Landscape - The electronic medical record (EMR) rating system is expected to be completed by the end of this year, with 91.26% of tertiary public hospitals achieving the required standards [6] - The market remains fragmented, with the top three companies holding less than 30% of the market share, indicating potential for consolidation [7] - The company is focusing on enhancing its competitive edge in the internet healthcare sector, which is becoming a necessity for users [11]

Financial Performance - The company's revenue for Q3 2022 was ¥775,042,099.83, representing a 4.94% increase year-over-year[6] - Net profit attributable to shareholders decreased by 50.60% to ¥73,136,649.61 compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥57,133,124.80, down 56.80% year-over-year[6] - The basic earnings per share (EPS) was ¥0.0341, a decrease of 52.57% compared to the previous year[6] - For the first nine months of 2022, the company achieved operating revenue of CNY 1,870.97 million, a year-on-year increase of 6.13%[25] - The net profit attributable to shareholders decreased by 46.08% to CNY 140.03 million, while the net profit after deducting non-recurring gains and losses fell by 42.64% to CNY 126.06 million[25] - Total comprehensive income attributable to the parent company was CNY 140,033,895.29, down from CNY 259,722,369.73 in the previous period, representing a decrease of approximately 46%[49] - Basic and diluted earnings per share were both CNY 0.0652, compared to CNY 0.1218 and CNY 0.1198 in the previous period, indicating a decline of about 46%[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,466,826,687.62, a decrease of 0.39% from the end of the previous year[6] - The total assets amounted to ¥7,466,826,687.62, slightly down from ¥7,496,296,725.89[39] - Total liabilities decreased to ¥2,310,810,177.92 from ¥2,322,891,629.90, showing a reduction of approximately 0.52%[39] - The company's equity attributable to shareholders was ¥5,094,434,746.24, a slight decrease from ¥5,099,946,697.98[39] - Long-term investments increased to ¥522,732,408.90 from ¥510,796,772.39, reflecting a growth of about 4.1%[39] Cash Flow - Cash flow from operating activities showed a net outflow of ¥239,875,855.68, reflecting a 4.29% increase in outflow compared to the previous year[6] - Net cash flow from operating activities was -CNY 239,875,855.68, an improvement from -CNY 250,615,004.14 in the previous period[50] - Cash inflow from operating activities totaled CNY 1,856,602,763.06, up from CNY 1,520,788,754.07, marking an increase of approximately 22%[47] - Cash outflow from operating activities increased to CNY 2,096,478,618.74 from CNY 1,771,403,758.21, reflecting a rise of about 18%[50] - Cash inflow from financing activities decreased significantly to CNY 136,739,595.66 from CNY 1,040,742,355.97, a decline of approximately 87%[50] - Cash and cash equivalents at the end of the period were CNY 914,329,080.92, down from CNY 1,022,597,494.11, representing a decrease of about 10.6%[50] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 77,901[13] - The major shareholders include Zhou Wei and Wang Ying, holding 8.22% and 4.96% of shares respectively, with a total of 176,474,241 and 106,529,129 shares[18] - The company transferred 42,830,000 shares to four private equity funds, with a total of 77,749,000 shares held by these funds as of the reporting period[21] - The top ten unrestricted shareholders hold a total of 106,205,970 shares, with Shanghai Yunxin Venture Capital Co., Ltd. being the largest[18] - Liu Ning transferred 31,684,667 shares to four private equity funds, which collectively hold the same number of shares as of the reporting period[21] - Zhou Cheng holds 63,050,000 shares, all through a margin trading account[21] - The company has established action agreements among several private equity funds, indicating coordinated shareholder actions[20] - The total number of shares held by the top ten unrestricted shareholders is significant, reflecting strong institutional interest[18] - The company has engaged in internal share transfers among its major shareholders, enhancing control dynamics[21] - The report indicates ongoing strategic maneuvers in shareholder structure, which may impact future governance and decision-making[20] - The company continues to explore market expansion and strategic partnerships through its shareholder agreements[20] Operational Highlights - The company reported a significant increase in development expenditures by 64.69% year-to-date, indicating a focus on project development[11] - The medical health information business accounted for 82.59% of total revenue, with a 1.83% year-on-year increase, while internet health business revenue grew by 32.88% to represent 17.41% of total revenue[25] - The company signed 39 new contracts for projects worth over CNY 10 million, including 17 WiNEX projects, showing significant growth compared to 29 contracts in the previous year[26] - The company received government subsidies totaling CNY 91.63 million, approximately 24.23% of the net profit attributable to shareholders for the year 2021[32] Expenses - Financial expenses increased by 75.61% year-over-year, primarily due to the accrual of interest on convertible bonds[12] - The company experienced a 54.79% decline in investment income compared to the previous year, attributed to increased losses from joint ventures[12] - Total operating costs increased to ¥1,745,785,513.46, up from ¥1,493,835,086.10, reflecting a significant rise in operating costs by about 16.86%[40] - Research and development expenses for the current period were ¥211,666,765.92, compared to ¥173,190,397.55 in the previous period, indicating a growth of approximately 22.2%[40] - The company reported a significant increase in sales expenses, which rose to ¥298,454,115.00 from ¥252,274,434.24, marking an increase of approximately 18.3%[40] Audit Information - The company did not conduct an audit for the third quarter report[51]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders for the same period was 200 million RMB, up 10% compared to the previous year[18]. - The company's operating revenue for the reporting period was ¥1,095,923,090.27, representing a year-on-year increase of 6.98%[26]. - Net profit attributable to shareholders decreased by 40.09% to ¥66,897,245.68 compared to the same period last year[26]. - The net profit after deducting non-recurring gains and losses was ¥68,926,834.22, down 21.25% year-on-year[26]. - Future guidance indicates a projected revenue growth of 25% for the full year 2022[18]. - The company reported a total revenue of 1.5 billion RMB for the first half of 2022, representing a year-over-year increase of 20%[200]. - The company has set a revenue guidance of 3.2 billion RMB for the full year 2022, reflecting an expected growth of 15% compared to 2021[200]. User Growth - User data showed an increase in active users to 5 million, reflecting a growth rate of 20% year-on-year[18]. - User data showed an increase in active users to 10 million, up from 8 million in the previous year, indicating a growth rate of 25%[200]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[18]. - Market expansion efforts have led to a 40% increase in sales in the Southeast Asia region, with plans to enter two additional markets by the end of 2022[200]. Product Development - New product launches are expected to contribute an additional 300 million RMB in revenue for the second half of 2022[18]. - New product launches contributed to 30% of total revenue, highlighting the importance of innovation in driving sales[200]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing service delivery and user experience[200]. Research and Development - The company has invested 100 million RMB in R&D for new technologies, aiming to enhance its product offerings and improve user experience[18]. - Company研发投入为2.77亿元，占营业收入的25.27%[46]. - Research and development expenses increased by 15.50% to ¥277,378,922.24 from ¥240,155,515.11 in the previous year[66]. Strategic Partnerships and Acquisitions - Strategic partnerships are being pursued to enhance service capabilities and expand the customer base[18]. - The company completed a strategic acquisition of a local tech firm for 500 million RMB to bolster its capabilities in AI[200]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year[6]. - The company reported a significant increase in financial expenses by 104.20%, amounting to ¥19,417,026.46, primarily due to interest accrued on convertible bonds[66]. - The company reported a net cash outflow from financing activities of -¥129,989,317.25, a decrease of 123.79% compared to the previous year due to the absence of funds raised from issuing convertible bonds[66]. Risk Management - The company is actively managing risks related to technology development and market competition, with a focus on maintaining operational stability[5]. - The company faces risks related to technology and product development, emphasizing the need for continuous innovation to maintain market advantages[106]. - Increased competition in the healthcare information industry necessitates enhanced management measures and R&D investment to sustain core competitive advantages[107]. - The ongoing COVID-19 pandemic poses risks to business operations, requiring proactive monitoring and response strategies[113]. Shareholder Information - The company reported a total of 73,561 shareholders at the end of the reporting period, with the largest shareholder, Zhou Wei, holding 8.22% of the shares[180]. - The company has repurchased 14,256,400 shares, accounting for 0.66% of the total share capital, with a total transaction amount of 120,623,771.16 yuan[164]. - The company’s total share capital increased by 1,298,781 shares due to stock option exercises during the reporting period[172]. Compliance and Governance - The company has maintained compliance with relevant laws and regulations, ensuring transparency and timely information disclosure to investors[134]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[142]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[138].